ZyVersa Therapeutics, Inc. (ZVSA)

OTCMKTS · Delayed Price · Currency is USD
0.260
-0.003 (-0.95%)
At close: Feb 27, 2026
-77.97%
Market Cap 2.10M
Revenue (ttm) n/a
Net Income (ttm) -25.70M
Shares Out 8.10M
EPS (ttm) -5.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,698
Average Volume 45,327
Open 0.260
Previous Close 0.263
Day's Range 0.260 - 0.271
52-Week Range 0.110 - 1.940
Beta 0.81
RSI 62.13
Earnings Date Mar 26, 2026

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol ZVSA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.